Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Because robust human safety data are limited, it is difficult to give a definitive side-effect profile with meaningful incidence rates
GSH levels were enriched in the TIF compared with serum in mouse models of cancer and in human patients with cancer
Phase 2 data is promising
Study population and exposure The study population comprised adults (18 years) with diagnosed MASLD who initiated either combination therapy (GLP-1RAs plus SGLT2i) or monotherapy (SGLT2i alone) between January 2017 and October 2024
US$ 24.84
US$ 23.59
US$ 23.34
US$ 28.17
